Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

0.7732 -0.0368 (-4.54%)
Streaming Delayed Price Updated: 9:47 AM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Which stocks are moving after the closing bell on Friday?
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Top movers in Friday's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Earnings Scheduled For May 12, 2025
Via Benzinga
Earnings Preview: Coherus BioSciences
Via Benzinga
Recap: Coherus BioSciences Q4 Earnings
Via Benzinga
Earnings Preview For Coherus BioSciences
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Earnings Scheduled For March 10, 2025
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Coherus Biosciences Stock Tumbled on Thursday
The company fell well short of expectations for its fourth quarter. 
Via The Motley Fool
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
Why Coherus BioSciences Stock Jumped Today
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses. 
Via The Motley Fool
Why Coherus BioSciences Stock Is Sinking Today
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long. 
Via The Motley Fool
Why Coherus Biosciences Popped Today
Coherus is divesting its non-core ophthalmology franchise. 
Via The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the... 
Via Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. 
Via Benzinga
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price. 
Via InvestorPlace
Why Is B. Riley Financial (RILY) Stock Down 11% Today?
B. Riley Financial stock is falling on Monday as RILY investors react to reports of an SEC probe and the company's stance on the news. 
Via InvestorPlace
Topics Regulatory Compliance
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
Coherus BioSciences stock is rising on Monday as CHRS investors react to a $170 million divestment of its CIMERLI ophthalmology franchise. 
Via InvestorPlace
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.